Home / Intelligence / Blog / Verily to Acquire SignalPath, Expanding the Company’s Clinical Research Capabilities
Published August 30, 2021
Verily recently announced its first major acquisition, a software platform known as SignalPath. SignalPath’s flagship software, TrialPath, digitizes and modulates individual protocols in a clinical trial, from budgeting to tracking point-of-care communication. The acquisition would fold SignalPath into Baseline, Verily’s clinical research platform designed to improve clinical trial execution, help research manage their clinical trials, and explore flexible study options for decentralized and hybrids trials as well as novel ways to capture real-world data (i.e., generated by novel sensors and biomarkers).
While many details of the agreement were not disclosed, including the financial terms, this deal could “set a new standard for clinical studies and evidence generation,” according to Amy Abernethy, MD, PhD, a former principal deputy commissioner at the FDA and current President of Clinical Studies Platforms at Verily. With a tech giant backing and a growing pipeline of digital technologies, including a virtual clinic that provides online care and coaching for chronic conditions, Verily can now use a new system to accelerate its research and trial processes, to quickly establish its presence in the DTx.
Written by Crystal Zhao and Kate Watkins
Related Intelligence
Briefs
Advances in International Health Technology Assessment Collaboration
How will Joint Clinical Assessment impact patient access to medicines in Europe? Joint clinical assessment (JCA) has been implemented for new cancer medicines and advanced therapy medicinal products (ATMP) from January 2025 in the European Union (EU). The first panel session at the London 2025 Galien Foundation Forum focused on international health technology assessment (HTA) […]
Read More
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted […]
Read More
Webinars
Making Segmentation Real with AI Webinar Series
September 30, 2025 | 1:00 PM ET & October 16, 2025 | 12:00 PM ET
“This is the gold standard approach to segmentation.” —Trinity Life Sciences’ client and repeat Weave user Life sciences companies often struggle with fragmented data, complex segmentation solutions, and difficulty translating analytical segments into actionable engagement strategies. Join us for a two-part webinar series showcasing two of Trinity’s AI-enabled solutions, Real Insights Weave and Auras, designed to […]
Sign Up Now